| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 5th October 2020 | Paula Ragan | 1,797 | Open or private sale | $7.00 | $12,579.00 |
| 2nd October 2020 | Paula Ragan | 603 | Open or private sale | $7.00 | $4,221.00 |
| 21st September 2020 | Adam S. Mostafa | 10,834 | Open or private sale | $7.08 | $76,704.72 |
| 9th September 2020 | Paula Ragan | 8,840 | Open or private sale | $8.04 | $71,073.60 |
| 9th September 2020 | Derek M Meisner | 8,334 | Open or private sale | $8.05 | $67,088.70 |
| 9th September 2020 | Renato Skerlj | 5,834 | Open or private sale | $8.05 | $46,963.70 |
| 2nd September 2020 | Paula Ragan | 2,400 | Open or private sale | $7.99 | $19,176.00 |
| 17th August 2020 | Paula Ragan | 44,825 | Grant/award etc. | $0.00 | |
| 17th August 2020 | Renato Skerlj | 8,750 | Grant/award etc. | $0.00 | |
| 17th August 2020 | Adam S. Mostafa | 16,250 | Grant/award etc. | $0.00 |
Arsanis
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Biotechnology company engages in developing human antibodies for treating infectious diseases. Operates as a biotechnology company which engages indeveloping human antibodies.
Ticker: ASNS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1501697
Employees: 15
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $104 M (0%)
Assets, Current: $110 M (-14%)
Property, Plant and Equipment, Net: $421 Th (0%)
Other Assets, Noncurrent: $3 M (78%)
Assets: $143 M (-11%)
Accounts Payable, Current: $2 M (-11%)
Accrued Liabilities, Current: $8 M (0%)
Liabilities, Current: $11 M (14%)
Other Liabilities, Noncurrent: $26 Th (62%)
Liabilities: $38 M (19%)
Common Stock, Value, Issued: $16 Th (0%)
Additional Paid in Capital, Common Stock: $263 M (0%)
Retained Earnings (Accumulated Deficit): $158 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $119 Th (0%)
Stockholders' Equity (Parent): $105 M (0%)
Liabilities and Equity: $143 M (-11%)
Revenue: $0 (-100%)
Research and Development: $9 M (-48%)
General and Administrative Expenses: $5 M (-46%)
Operating Income/Loss: $15 M (-41%)
Other Income, net: $486 Th (-45%)
Provision for income taxes: $0 (-100%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
